NO20062398L - Daily oral controlled release oxycodone dosage form - Google Patents

Daily oral controlled release oxycodone dosage form

Info

Publication number
NO20062398L
NO20062398L NO20062398A NO20062398A NO20062398L NO 20062398 L NO20062398 L NO 20062398L NO 20062398 A NO20062398 A NO 20062398A NO 20062398 A NO20062398 A NO 20062398A NO 20062398 L NO20062398 L NO 20062398L
Authority
NO
Norway
Prior art keywords
profiles
dosage form
controlled release
daily oral
oral controlled
Prior art date
Application number
NO20062398A
Other languages
Norwegian (no)
Inventor
Nishit Modi
Stephen Hwang
Padmaja Shivanand
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20062398L publication Critical patent/NO20062398L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Det er frembragt oksykodonformuleringer som produserer i det vesentlige flate, in vivo tilstandsstabile plasmaprofiler. Toleransenivåer i samband med slike profiler og toleransenivåer i samband med bifasiske profiler er vist å ikke være statistisk ulike. De i det vesentlige flate, in vivo tilstandsstabile plasmaprofiler blir produsert av doseringsformer med i det vesentlige nulte ordens in vitro frigjøringsprofiler. Slike frigjøringsprofiler produserer for lav enkeltdose in vivo Cmaks-nivåer som kan redusere sannsynligheten for skadelige bivirkninger.Oxycodone formulations have been produced which produce substantially flat, in vivo state-stable plasma profiles. Tolerance levels associated with such profiles and tolerance levels associated with biphasic profiles have been shown to be not statistically different. The substantially flat, in vivo state-stable plasma profiles are produced by dosage forms having substantially zero order in vitro release profiles. Such release profiles produce too low single dose in vivo Cmax levels that can reduce the likelihood of adverse side effects.

NO20062398A 2003-10-29 2006-05-26 Daily oral controlled release oxycodone dosage form NO20062398L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51588003P 2003-10-29 2003-10-29
PCT/US2004/036132 WO2005041968A2 (en) 2003-10-29 2004-10-28 Once-a-day, oral, controlled-release, oxycodone dosage forms

Publications (1)

Publication Number Publication Date
NO20062398L true NO20062398L (en) 2006-07-27

Family

ID=34549453

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062398A NO20062398L (en) 2003-10-29 2006-05-26 Daily oral controlled release oxycodone dosage form

Country Status (14)

Country Link
EP (1) EP1677798A2 (en)
JP (1) JP2007509979A (en)
KR (1) KR20060108690A (en)
CN (1) CN1933837A (en)
AU (1) AU2004285547A1 (en)
BR (1) BRPI0415639A (en)
CA (1) CA2546691A1 (en)
EC (1) ECSP066534A (en)
IL (1) IL175193A0 (en)
MA (1) MA28215A1 (en)
NO (1) NO20062398L (en)
RU (1) RU2006118323A (en)
WO (1) WO2005041968A2 (en)
ZA (1) ZA200604310B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120050528A (en) 1999-10-29 2012-05-18 유로-셀티크 소시에떼 아노뉨 Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (en) * 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
JP2011511782A (en) 2008-02-12 2011-04-14 アボット・ラボラトリーズ Extended release hydrocodone acetaminophen and related methods and uses
CA2723438C (en) 2008-05-09 2016-10-11 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
ES2560210T3 (en) 2009-07-22 2016-02-17 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opiates
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
CA2832436C (en) * 2010-04-07 2018-08-14 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
CA2808541C (en) 2010-09-02 2019-01-08 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
BR112013005194A2 (en) 2010-09-02 2016-05-03 Gruenenthal Gmbh tamper-resistant dosage form comprising inorganic salt
WO2013017242A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
PT2736495T (en) 2011-07-29 2017-11-30 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AR090695A1 (en) 2012-04-18 2014-12-03 Gruenenthal Gmbh PHARMACEUTICAL DOSAGE FORM RESISTANT TO ADULTERATION AND RESISTANT TO IMMEDIATE RELEASE OF DOSE
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
BR112015026549A2 (en) 2013-05-29 2017-07-25 Gruenenthal Gmbh tamper-proof dosage form containing one or more particles
JP6449871B2 (en) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Anti-modified dosage form containing ethylene-vinyl acetate polymer
CA2931553C (en) 2013-11-26 2022-01-18 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
BR112017021475A2 (en) 2015-04-24 2018-07-10 Gruenenthal Gmbh tamper-resistant dosage form with immediate release and resistance to solvent extraction
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
JP6875501B2 (en) 2016-08-10 2021-05-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト A pharmaceutical composition comprising an Akt protein kinase inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
UA81224C2 (en) * 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US20040010000A1 (en) * 2002-04-29 2004-01-15 Ayer Atul D. Methods and dosage forms for controlled delivery of oxycodone
BR0304960A (en) * 2002-05-31 2005-01-04 Alza Corp Dosage forms and compositions for osmotic release of varying dosages of oxycodone

Also Published As

Publication number Publication date
MA28215A1 (en) 2006-10-02
WO2005041968A2 (en) 2005-05-12
CN1933837A (en) 2007-03-21
KR20060108690A (en) 2006-10-18
ECSP066534A (en) 2006-11-24
IL175193A0 (en) 2008-04-13
CA2546691A1 (en) 2005-05-12
BRPI0415639A (en) 2006-12-12
AU2004285547A1 (en) 2005-05-12
EP1677798A2 (en) 2006-07-12
ZA200604310B (en) 2007-11-28
WO2005041968A3 (en) 2006-06-22
RU2006118323A (en) 2007-12-10
JP2007509979A (en) 2007-04-19

Similar Documents

Publication Publication Date Title
NO20062398L (en) Daily oral controlled release oxycodone dosage form
TW200718689A (en) 2-Amino-quinazolin-5-ones
CY1112478T1 (en) KINAZOLINONE COMPOUNDS AS ANTI-CANCER FACTORS
GEP20125701B (en) Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
MXPA05013142A (en) Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents.
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
MY147393A (en) Administration of dipeptidyl peptidase inhibitors
TW200630093A (en) Dose forms
MY143604A (en) 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones
TW200716628A (en) Novel compounds
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
NZ588913A (en) Liver cancer drug
EG25822A (en) Quinolinyl-pyrrolopyrazoles
WO2004006859A3 (en) Platinum compound
CO6270217A2 (en) GALENIC FORMULATIONS OF ALISQUIRENO AND VALSARTAN
WO2008052139A3 (en) Ultra low dose doxepin and methods of using the same to treat sleep disorders
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
EP1503748A4 (en) Drugs for mitigating taxane-induced neurotoxicity
RU2007122391A (en) S-MIRTAZAPINE FOR TIDAL TREATMENT
MX2010005009A (en) Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction.
EA200801890A1 (en) MEANS FOR THE TREATMENT OF NOISE IN THE EARS
PL1718651T3 (en) 7h-pyrrolopyrimidine derivatives
TW200616951A (en) Indole derivatives, their manufacture and use as pharmaceutial agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application